📄 Abstract
Finerenone is a Novel selective Non-steroidal Mineralocorticoids Receptor Antagonist. Finerenone is indicated for the treatment of Chronic kidney disease (stage 3 and stage 4) associated with type 2 diabetes in adults. Finerenone blocks the MR receptor so that the progression of chronic kidney disease is control. Finerenone belongs to the BCS class-II, low solubility and low half life and bioavailbility.
🏷️ Keywords
📚 How to Cite:
Dr.Sanjay Prajapati, Dr. Pratik Prajapati, Kajal Gondaliya , A COMPREHENSIVE REVIEW ARTICLE ON FINERENONE , Volume 8 , Issue 2, february 2023, EPRA International Journal of Research & Development (IJRD) ,